O	0	12	Inactivation	Inactivation	NN	B-NP
O	13	15	of	of	IN	B-PP
O	16	24	androgen	androgen	NN	B-NP
O	24	25	-	-	HYPH	B-NP
O	25	32	induced	induce	VBN	I-NP
O	33	42	regulator	regulator	NN	I-NP
O	43	47	ARD1	ARD1	NN	I-NP
O	48	56	inhibits	inhibit	VBZ	B-VP
O	57	65	androgen	androgen	NN	B-NP
O	66	74	receptor	receptor	NN	I-NP
O	75	86	acetylation	acetylation	NN	I-NP
O	87	90	and	and	CC	O
B-Organ	91	99	prostate	prostate	NN	B-NP
O	100	113	tumorigenesis	tumorigenesis	NN	I-NP
O	113	114	.	.	.	O

O	116	124	Androgen	Androgen	NN	B-NP
O	125	134	signaling	signaling	NN	I-NP
O	135	142	through	through	IN	B-PP
O	143	151	androgen	androgen	NN	B-NP
O	152	160	receptor	receptor	NN	I-NP
O	161	162	(	(	(	O
O	162	164	AR	AR	NN	B-NP
O	164	165	)	)	)	O
O	166	168	is	be	VBZ	B-VP
O	169	177	critical	critical	JJ	B-ADJP
O	178	181	for	for	IN	B-PP
B-Organ	182	190	prostate	prostate	NN	B-NP
O	191	204	tumorigenesis	tumorigenesis	NN	I-NP
O	204	205	.	.	.	O

O	206	211	Given	Give	VBN	B-VP
O	212	216	that	that	IN	B-SBAR
O	217	219	AR	AR	NN	B-NP
O	219	220	-	-	HYPH	B-NP
O	220	228	mediated	mediate	VBN	I-NP
O	229	233	gene	gene	NN	I-NP
O	234	244	regulation	regulation	NN	I-NP
O	245	247	is	be	VBZ	B-VP
O	248	256	enhanced	enhance	VBN	I-VP
O	257	259	by	by	IN	B-PP
O	260	262	AR	AR	NN	B-NP
O	263	275	coregulators	coregulator	NNS	I-NP
O	275	276	,	,	,	O
O	277	289	inactivation	inactivation	NN	B-NP
O	290	292	of	of	IN	B-PP
O	293	298	those	those	DT	B-NP
O	299	311	coregulators	coregulator	NNS	I-NP
O	312	314	is	be	VBZ	B-VP
O	315	323	emerging	emerge	VBG	I-VP
O	324	326	as	as	IN	B-PP
O	327	328	a	a	DT	B-NP
O	329	338	promising	promising	JJ	I-NP
O	339	346	therapy	therapy	NN	I-NP
O	347	350	for	for	IN	B-PP
B-Cancer	351	359	prostate	prostate	NN	B-NP
I-Cancer	360	366	cancer	cancer	NN	I-NP
O	367	368	(	(	(	O
B-Cancer	368	371	PCa	PCa	NN	B-NP
O	371	372	)	)	)	O
O	372	373	.	.	.	O

O	374	378	Here	Here	RB	B-ADVP
O	378	379	,	,	,	O
O	380	382	we	we	PRP	B-NP
O	383	387	show	show	VBP	B-VP
O	388	392	that	that	IN	B-SBAR
O	393	396	the	the	DT	B-NP
O	397	398	N	N	NN	I-NP
O	398	399	-	-	HYPH	O
O	399	416	acetyltransferase	acetyltransferase	NN	B-NP
O	417	423	arrest	arrest	NN	I-NP
O	423	424	-	-	HYPH	O
O	424	430	defect	defect	NN	B-NP
O	431	432	1	1	CD	I-NP
O	433	440	protein	protein	NN	I-NP
O	441	442	(	(	(	O
O	442	446	ARD1	ARD1	NN	B-NP
O	446	447	)	)	)	O
O	448	457	functions	function	VBZ	B-VP
O	458	460	as	as	IN	B-PP
O	461	462	a	a	DT	B-NP
O	463	469	unique	unique	JJ	I-NP
O	470	472	AR	AR	NN	I-NP
O	473	482	regulator	regulator	NN	I-NP
O	483	485	in	in	IN	B-PP
B-Cell	486	489	PCa	PCa	NN	B-NP
I-Cell	490	495	cells	cell	NNS	I-NP
O	495	496	.	.	.	O

O	497	501	ARD1	ARD1	NN	B-NP
O	502	504	is	be	VBZ	B-VP
O	505	507	up	up	RB	B-ADVP
O	507	508	-	-	HYPH	B-NP
O	508	517	regulated	regulate	VBN	B-VP
O	518	520	in	in	IN	B-PP
O	521	526	human	human	JJ	B-NP
B-Cell	527	530	PCa	PCa	NN	I-NP
I-Cell	531	535	cell	cell	NN	I-NP
I-Cell	536	541	lines	line	NNS	I-NP
O	542	545	and	and	CC	O
B-Cancer	546	553	primary	primary	JJ	B-NP
I-Cancer	554	559	tumor	tumor	NN	I-NP
I-Cancer	560	568	biopsies	biopsy	NNS	I-NP
O	568	569	.	.	.	O

O	570	573	The	The	DT	B-NP
O	574	584	expression	expression	NN	I-NP
O	585	587	of	of	IN	B-PP
O	588	592	ARD1	ARD1	NN	B-NP
O	593	596	was	be	VBD	B-VP
O	597	606	augmented	augment	VBN	I-VP
O	607	609	by	by	IN	B-PP
O	610	619	treatment	treatment	NN	B-NP
O	620	624	with	with	IN	B-PP
O	625	634	synthetic	synthetic	JJ	B-NP
O	635	643	androgen	androgen	NN	I-NP
O	644	645	(	(	(	O
O	645	650	R1881	R1881	NN	B-NP
O	650	651	)	)	)	O
O	652	658	unless	unless	IN	B-SBAR
O	659	661	AR	AR	NN	B-NP
O	662	664	is	be	VBZ	B-VP
O	665	674	deficient	deficient	JJ	B-ADJP
O	675	677	or	or	CC	O
O	678	680	is	be	VBZ	B-VP
O	681	690	inhibited	inhibit	VBN	I-VP
O	691	693	by	by	IN	B-PP
O	694	696	AR	AR	NN	B-NP
O	696	697	-	-	HYPH	B-NP
O	697	705	specific	specific	JJ	I-NP
O	706	711	siRNA	siRNA	NN	I-NP
O	712	714	or	or	CC	I-NP
O	715	723	androgen	androgen	NN	I-NP
O	724	733	inhibitor	inhibitor	NN	I-NP
O	734	746	bicalutamide	bicalutamide	NN	I-NP
O	747	748	(	(	(	O
O	748	755	Casodex	Casodex	NN	B-NP
O	755	756	)	)	)	O
O	756	757	.	.	.	O

O	758	767	Depletion	Depletion	NN	B-NP
O	768	770	of	of	IN	B-PP
O	771	775	ARD1	ARD1	NN	B-NP
O	776	778	by	by	IN	B-PP
O	779	784	shRNA	shRNA	NN	B-NP
O	785	795	suppressed	suppress	VBD	B-VP
B-Cell	796	799	PCa	PCa	NN	B-NP
I-Cell	800	804	cell	cell	NN	I-NP
O	805	818	proliferation	proliferation	NN	I-NP
O	818	819	,	,	,	O
O	820	829	anchorage	anchorage	NN	B-NP
O	829	830	-	-	HYPH	B-NP
O	830	841	independent	independent	JJ	I-NP
O	842	848	growth	growth	NN	I-NP
O	848	849	,	,	,	O
O	850	853	and	and	CC	O
B-Cancer	854	863	xenograft	xenograft	NN	B-NP
I-Cancer	864	869	tumor	tumor	NN	I-NP
O	870	879	formation	formation	NN	I-NP
O	880	882	in	in	IN	B-PP
O	883	887	SCID	SCID	NN	B-NP
O	888	892	mice	mouse	NNS	I-NP
O	892	893	,	,	,	O
O	894	904	suggesting	suggest	VBG	B-VP
O	905	909	that	that	IN	B-SBAR
O	910	912	AR	AR	NN	B-NP
O	912	913	-	-	HYPH	B-NP
O	913	922	dependent	dependent	JJ	I-NP
O	923	927	ARD1	ARD1	NN	I-NP
O	928	938	expression	expression	NN	I-NP
O	939	941	is	be	VBZ	B-VP
O	942	954	biologically	biologically	RB	B-ADVP
O	955	962	germane	germane	NN	B-NP
O	962	963	.	.	.	O

O	964	971	Notably	Notably	RB	B-ADVP
O	971	972	,	,	,	O
O	973	977	ARD1	ARD1	NN	B-NP
O	978	981	was	be	VBD	B-VP
O	982	990	critical	critical	JJ	B-ADJP
O	991	994	for	for	IN	B-PP
O	995	1012	transcriptionally	transcriptionally	RB	B-VP
O	1013	1023	regulating	regulate	VBG	I-VP
O	1024	1025	a	a	DT	B-NP
O	1026	1032	number	number	NN	I-NP
O	1033	1035	of	of	IN	B-PP
O	1036	1038	AR	AR	NN	B-NP
O	1039	1045	target	target	NN	I-NP
O	1046	1051	genes	gene	NNS	I-NP
O	1052	1056	that	that	WDT	B-NP
O	1057	1060	are	be	VBP	B-VP
O	1061	1069	involved	involve	VBN	I-VP
O	1070	1072	in	in	IN	B-PP
B-Organ	1073	1081	prostate	prostate	NN	B-NP
O	1082	1095	tumorigenesis	tumorigenesis	NN	I-NP
O	1095	1096	.	.	.	O

O	1097	1108	Furthermore	Furthermore	RB	B-ADVP
O	1108	1109	,	,	,	O
O	1110	1114	ARD1	ARD1	NN	B-NP
O	1115	1125	interacted	interact	VBD	B-VP
O	1126	1136	physically	physically	RB	B-ADVP
O	1137	1141	with	with	IN	B-PP
O	1142	1145	and	and	CC	O
O	1146	1156	acetylated	acetylate	VBN	B-VP
O	1157	1160	the	the	DT	B-NP
O	1161	1163	AR	AR	NN	I-NP
O	1164	1171	protein	protein	NN	I-NP
O	1172	1174	in	in	FW	B-ADVP
O	1175	1179	vivo	vivo	FW	I-ADVP
O	1180	1183	and	and	CC	O
O	1184	1186	in	in	FW	B-ADVP
O	1187	1192	vitro	vitro	FW	I-ADVP
O	1192	1193	.	.	.	O

O	1194	1201	Because	Because	IN	B-SBAR
O	1202	1204	AR	AR	NN	B-NP
O	1204	1205	-	-	HYPH	B-NP
O	1205	1209	ARD1	ARD1	NN	I-NP
O	1210	1221	interaction	interaction	NN	I-NP
O	1222	1233	facilitated	facilitate	VBD	B-VP
O	1234	1237	the	the	DT	B-NP
O	1238	1240	AR	AR	NN	I-NP
O	1241	1248	binding	bind	VBG	B-VP
O	1249	1251	to	to	TO	B-PP
O	1252	1255	its	its	PRP$	B-NP
O	1256	1264	targeted	target	VBN	I-NP
O	1265	1274	promoters	promoter	NNS	I-NP
O	1275	1278	for	for	IN	B-PP
O	1279	1283	gene	gene	NN	B-NP
O	1284	1297	transcription	transcription	NN	I-NP
O	1297	1298	,	,	,	O
O	1299	1301	we	we	PRP	B-NP
O	1302	1309	propose	propose	VBP	B-VP
O	1310	1314	that	that	IN	B-SBAR
O	1315	1319	ARD1	ARD1	NN	B-NP
O	1320	1329	functions	function	VBZ	B-VP
O	1330	1332	as	as	IN	B-PP
O	1333	1334	a	a	DT	B-NP
O	1335	1341	unique	unique	JJ	I-NP
O	1342	1344	AR	AR	NN	I-NP
O	1345	1354	regulator	regulator	NN	I-NP
O	1355	1358	and	and	CC	O
O	1359	1364	forms	form	VBZ	B-VP
O	1365	1366	a	a	DT	B-NP
O	1367	1375	positive	positive	JJ	I-NP
O	1376	1384	feedback	feedback	NN	I-NP
O	1385	1389	loop	loop	NN	I-NP
O	1390	1393	for	for	IN	B-PP
O	1394	1396	AR	AR	NN	B-NP
O	1396	1397	-	-	HYPH	B-NP
O	1397	1406	dependent	dependent	JJ	I-NP
B-Organ	1407	1415	prostate	prostate	NN	I-NP
O	1416	1429	tumorigenesis	tumorigenesis	NN	I-NP
O	1429	1430	.	.	.	O

O	1431	1441	Disruption	Disruption	NN	B-NP
O	1442	1444	of	of	IN	B-PP
O	1445	1447	AR	AR	NN	B-NP
O	1447	1448	-	-	HYPH	B-NP
O	1448	1452	ARD1	ARD1	NN	I-NP
O	1453	1465	interactions	interaction	NNS	I-NP
O	1466	1469	may	may	MD	B-VP
O	1470	1472	be	be	VB	I-VP
O	1473	1474	a	a	DT	B-NP
O	1475	1481	potent	potent	JJ	I-NP
O	1482	1494	intervention	intervention	NN	I-NP
O	1495	1498	for	for	IN	B-PP
O	1499	1507	androgen	androgen	NN	B-NP
O	1507	1508	-	-	HYPH	B-NP
O	1508	1517	dependent	dependent	JJ	I-NP
B-Cancer	1518	1521	PCa	PCa	NN	I-NP
O	1522	1529	therapy	therapy	NN	I-NP
O	1529	1530	.	.	.	O

